DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: LGMD2B, on the other hand, also known as dysferlinopathy, has two clinical phenotypes based on clinical manifestations, particularly the distribution of muscle weakness [2,3,10]: 1) LGMD2B (proximal onset) phenotype, with proximal weakness with progressive distal involvement, and 2) Miyoshi distal myopathy (distal onset) phenotype, which is previously of a different category due to the involvement of distal extremities (in contrast to LGMD diseases, which are proximal).